Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant in pediatric classic congenital adrenal hyperplasia
NL-OMON60962Phase 3Not yet recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atumelnant in congenital adrenal hyperplasia (CAH) (3 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events, Change from baseline in morning androstenedione at Week 8 and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
atumelnant
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NL-OMON60962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60962.